EL7.AI पर प्रदान की गई जानकारी केवल शैक्षिक और सूचनात्मक उद्देश्यों के लिए है और यह वित्तीय सलाह नहीं है।
EL7.AI पर प्रदान की गई जानकारी केवल शैक्षिक और सूचनात्मक उद्देश्यों के लिए है और यह वित्तीय सलाह नहीं है।
इस कंटेंट को एक्सेस करने के लिए मुफ्त साइन अप करें
मुफ्त अकाउंट बनाएंPalisade Bio (Nasdaq: PALI) announced positive topline results from its Phase 1b study of PALI-2108, an oral PDE4 inhibitor targeting Crohn's disease. The study demonstrated significant clinical activity, with the drug showing a 47.5% reduction in the SES-CD score, a key indicator of endoscopic improvement. Notably, 40% of the participating patients achieved both endoscopic response and remission within just two weeks of treatment. The trial successfully met its primary endpoints for safety and tolerability, providing a strong foundation for further clinical development. Following these favorable results, the company plans to advance PALI-2108 into Phase 2 clinical trials for patients with moderate to severe Crohn's disease. This development marks a significant milestone for the biotech firm as it seeks to address unmet needs in fibrostenotic Crohn's disease.